Coming October: SITC releases its late-breaking abstract titles. We’ll add their presenting authors’ institutions to this guide once they’re out.

Takeda at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

Takeda brings 2 presentations to SITC 2026 in Phoenix. Its program centres on bispecific drugs that pair PD-1 or PD-L1 targeting with immune activation. It also describes a gamma delta T cell engager that links these immune cells to PD-L1 on solid tumors.

Organization	SITC 2026 Attendance
Takeda Tokyo, Japan
takeda.com Large pharma Japanese global pharmaceutical company with oncology among its core therapeutic areas.	Talk Thu Nov 5 2:05pm–2:15pm Part of Session III: ADC/iADC TAK-928 (IBI-363): A First-in-class PD-1/IL-2 α-bias Bispecific Fusion Protein Valley of the Sun Ballroom New agents Poster Sat Nov 7 12:30–1:30pm 6:40–8:10pm Preclinical development of TAK-505, a novel VD1 TCR x PD-L1 bispecific gamma delta T-cell engager (TCE) for the treatment of PD-L1-expressing solid tumors Exhibition Halls 4-6 · Poster 842 New agents

Organization

SITC 2026 Attendance

Takeda

Tokyo, Japan

takeda.com

Large pharma

Japanese global pharmaceutical company with oncology among its core therapeutic areas.

Talk

Thu Nov 5
2:05pm–2:15pm

Part of Session III: ADC/iADC

TAK-928 (IBI-363): A First-in-class PD-1/IL-2 α-bias Bispecific Fusion Protein

Valley of the Sun Ballroom